What can I say except that I think you are completely correct in what you say. Except for the obvious bashers and those with other obscure agendas, we're really all on the same side here. IMHO, the company is entering a new phase of its life; no longer a start up but with potential marketable products,it needs a new CFO who is capable of talking to Wall Street and who has good relationships with investors; it needs others in management who have business backgrounds and who can handle the transition and the future positioning of the company; it needs a large infusion of cash either from big pharma (preferable) or perhaps from venture, with some government money also seasoning the pot; in short, all those things (including peer-reviewed scientific publications, a key item) which make a successful company with successful products. IMHO, there is evidence which suggests that the company is acutely aware of these issues. I hope to see progress in these matters in the very near future. Have a good evening.
